Suppression of PU.1-linked TLR4 expression by cilostazol with decrease of cytokine production in macrophages from patients with rheumatoid arthritis

British Journal of Pharmacology

Volumn 168, Issue 6, 2013, Pages 1401-1411

  Park, S Y ^a   Lee, S W ^b   Baek, S H ^a   Lee, C W ^c   Lee, W S ^a   Rhim, B Y ^b   Hong, K W ^a   Kim, Chi Dae ^a,b  

^a Pusan National University School of Medicine   (South Korea)

^b Dong A University   (South Korea)

^c Wallace Memorial Baptist Hospital   (South Korea)

Author keywords

CIA; Cilostazol; Cytokine; MyD88; PU.1; RA Macrophages; TLR4

Indexed keywords

CILOSTAZOL; CYCLIC AMP; CYTOKINE; FORSKOLIN; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; ISOBUTYLMETHYLXANTHINE; LIPOPOLYSACCHARIDE; MYELOID DIFFERENTIATION FACTOR 88; PROTEOGLYCAN; SYNAPTOTAGMIN I; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR PU 1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; BONE EROSION; CELL LEVEL; CELL TRANSPORT; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRACELLULAR SIGNALING; KNEE; MACROPHAGE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS INHIBITION; RHEUMATOID ARTHRITIS; SYNOVIAL FLUID; SYNOVIOCYTE; SYNOVITIS; TRANSCRIPTION REGULATION; TREATMENT RESPONSE;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CELLS, CULTURED; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION; HUMANS; KNEE JOINT; MACROPHAGE ACTIVATION; MACROPHAGES; MALE; MICE; MICE, INBRED DBA; PHOSPHODIESTERASE 3 INHIBITORS; PROTO-ONCOGENE PROTEINS; SECOND MESSENGER SYSTEMS; TETRAZOLES; TOLL-LIKE RECEPTOR 4; TRANS-ACTIVATORS;

EID: 84874407730     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12021     Document Type: Article

References (34)

1. Abdollahi-Roodsaz S, Joosten LA, Roelofs MF, Radstake TR, Matera G, Popa C, et al. (2007). Inhibition of toll-like receptor 4 breaks the inflammatory loop in autoimmune destructive arthritis. Arthritis Rheum 56: 2957-2967.
2. Akira S, Takeda K, (2004). Toll-like receptor signalling. Nat Rev Immunol 4: 499-511.
3. Akira S, Takeda K, Kaisho T, (2001). Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2: 675-680.
4. Alexander SPH, Mathie A, Peters JA, (2011). Guide to Receptors and Channels (GRAC), 5th edn. Br. J. Pharmacol 164 (Suppl. 1): S1-S324.
5. Andreakos E, Sacre SM, Smith C, Lundberg A, Kiriakidis S, Stonehouse T, et al. (2004). Distinct pathways of LPS-induced NF-κB activation and cytokine production in human myeloid and nonmyeloid cells defined by selective utilization of MyD88 and Mal/TIRAP. Blood 103: 2229-2237.
6. Bai Y, Murakami H, Iwasa M, Sumi S, Yamada Y, Ushikoshi H, et al. (2011). Cilostazol protects the heart against ischaemia reperfusion injury in a rabbit model of myocardial infarction: focus on adenosine, nitric oxide and mitochondrial ATP-sensitive potassium channels. Clin Exp Pharmacol Physiol 38: 658-665.
7. Feldmann M, Brennan FM, Maini RN, (1996). Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 14: 397-440.
8. Firestein GS, (2005). Immunologic mechanisms in the pathogenesis of rheumatoid arthritis. J Clin Rheumatol 11 (Suppl.): S39-S44.
9. Firestein GS, Svaifler NJ, (1987). Peripheral blood and synovial fluid monocyte activation in inflammatory arthritis. II. Low levels of synovial fluid and synovial tissue interferon suggest that gamma-interferon is not the primary macrophage activating factor. Arthritis Rheum 30: 864-871.
10. Gohda J, Matsumura T, Inoue J, (2004). Cutting edge: TNFR-associated factor (TRAF) 6 is essential for MyD88-dependent pathway but not toll/IL-1 receptor domain-containing adaptor-inducing IFN-beta (TRIF)-dependent pathway in TLR signalling. J Immunol 173: 2913-2917.
11. Gordon S, (2003). Alternative activation of macrophages. Nat Rev Immunol 3: 23-35.
12. Handel ML, McMorrow LB, Gravallese EM, (1995). Nuclear factor-kB in rheumatoid synovium: localization of p50 and p65. Arthritis Rheum 38: 1762-1770.
13. Isomaki P, Luukkainen R, Saario R, Toivanen P, Punnonen J, (1996). Interleukin-10 functions as an antiinflammatory cytokine in rheumatoid synovium. Arthritis Rheum 39: 386-395.
14. Janeway CA Jr, Medzhitov R, (2002). Innate immune recognition. Annu Rev Immunol 20: 197-216.
15. Kawai T, Akira S, (2007). Signalling to NF-kB by Toll-like receptors. Trends Mol Med 13: 460-469.
16. Kim HY, Lee SW, Park SY, Baek SH, Lee CW, Hong KW, Kim CD, (2012). Efficacy of concurrent administration of cilostazol and methotrexate in rheumatoid arthritis: pharmacologic and clinical significance. Life Sci 91: 250-257.
17. Kyburz D, Rethage J, Seibl R, Lauener R, Gay RE, Carson DA, et al. (2003). Bacterial peptidoglycans but not CpG oligodeoxynucleotides activate synovial fibroblasts by toll-like receptor signalling. Arthritis Rheum 48: 642-650.
18. Lichtinger M, Ingram R, Hornef M, Bonifer C, Rehli M, (2007). Transcription factor PU.1 controls transcription start site positioning and alternative TLR4 promoter usage. J Biol Chem 282: 26874-26883.
19. Liu H, Ma Y, Cole SM, Zander C, Chen KH, Karras J, et al. (2003). Serine phosphorylation of STAT3 is essential for Mcl-1 expression and macrophage survival. Blood 102: 344-352.
20. Lubberts E, Koenders MI, Oppers-Walgreen B, van den, Bersselaar L, Coenen-de Roo CJ, Joosten LA, et al. (2004). Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum 50: 650-659.
21. McGrath J, Drummond G, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
22. Park SY, Lee JH, Kim YK, Kim CD, Rhim BY, Lee WS, et al. (2005). Cilostazol prevents remnant lipoprotein particle-induced monocyte adhesion to endothelial cells by suppression of adhesion molecules and monocyte chemoattractant protein-1 expression via lectin-like receptor for oxidized low-density lipoprotein receptor activation. J Pharmacol Exp Ther 312: 1241-1248.
23. Park SY, Lee JH, Kim CD, Lee WS, Park WS, Han J, et al. (2006). Cilostazol suppresses superoxide production and expression of adhesion molecules in human endothelial cells via mediation of cAMP-dependent protein kinase-mediated maxi-K channel activation. J Pharmacol Exp Ther 317: 1238-1245.
24. Park SY, Lee SW, Shin HK, Lee WS, Rhim BY, Hong KW, et al. (2010a). Cilostazol inhibits proliferation and enhances apoptosis of synovial cells from patient with rheumatoid arthritis with suppression of inflammatory cytokine production via Nrf2-mediated heme oxygenase-1 induction. Arthritis Rheum 62: 732-741.
25. Park WS, Jung WK, Lee DY, Moon C, Yea SS, Park SG, et al. (2010b). Cilostazol protects mice against endotoxin shock and attenuates LPS-induced cytokine expression in RAW 264.7 macrophages via MAPK inhibition and NF-kappaB inactivation: not involved in cAMP mechanisms. Int Immunopharmacol 10: 1077-1085.
26. Radstake TR, Roelofs MF, Jenniskens YM, Oppers-Walgreen B, van, Riel PL, Barrera P, et al. (2004). Expression of Toll-like receptors 2 and 4 in rheumatoid synovial tissue and regulation by proinflammatory cytokines interleukin-12 and interleukin-18 via interferon-g. Arthritis Rheum 50: 3856-3865.
27. Redlich K, Hayer S, Ricci R, David J-P, Tohidast-Akrad M, Kollias G, et al. (2002). Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest 110: 1419-1427.
28. Rehli M, Poltorak A, Schwarzfischer L, Krause SW, Andreesen R, Beutler B, (2000). PU.1 and interferon consensus sequence-binding protein regulate the myeloid expression of the human Toll-like receptor 4 genes. J Biol Chem 275: 9773-9781.
29. Schett G, Stach C, Zwerina J, Voll R, Manger B, (2008). How antirheumatic drugs protect joints from damage in rheumatoid arthritis. Arthritis Rheum 58: 2936-2948.
30. Shin HK, Kim YK, Kim KY, Lee JH, Hong KW, (2004). Remnant lipoprotein particles induce apoptosis in endothelial cells by NAD(P)H oxidase-mediated production of superoxide and cytokines via lectin-like oxidized low-density lipoprotein receptor-1 activation: prevention by cilostazol. Circulation 109: 1022-1028.
31. Simmonds RE, Foxwell BM, (2008). Signalling, inflammation and arthritis: NF-kappaB and its relevance to arthritis and inflammation. Rheumatology 47: 584-590.
32. Varani K, Padovan M, Vincenzi F, Targa M, Trotta F, Govoni M, et al. (2011). A2A and A3 adenosine receptor expression in rheumatoid arthritis: upregulation, inverse correlation with disease activity score and suppression of inflammatory cytokine and metalloproteinase release. Arthritis Res Ther 13: R197.
33. Williams RO, Feldmann M, Maini RN, (1992). Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci U S A 89: 9784-9788.
34. Zwerina J, Hayer S, Tohidast-Akrad M, Bergmeister H, Redlich K, Feige U, et al. (2004). Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum 50: 277-290.